<DOC>
	<DOCNO>NCT00345839</DOCNO>
	<brief_summary>The purpose study evaluate effect cinacalcet ( cinacalcet HCl Sensipar®/Mimpara® ) cardiovascular event death chronic kidney disease ( CKD ) patient secondary hyperparathyroidism ( HPT ) receive dialysis .</brief_summary>
	<brief_title>E.V.O.L.V.E . Trial™ : EValuation Of Cinacalcet Hydrochloride ( HCl ) Therapy Lower CardioVascular Events</brief_title>
	<detailed_description>Secondary HPT common people CKD . Patients secondary HPT often high parathyroid hormone ( PTH ) level may develop large parathyroid gland neck . Patients secondary HPT may bone disease ( osteodystrophy ) . This bone disease may cause bone pain , fracture , poor formation red blood cell . Other problem secondary HPT may include increase blood level calcium phosphorus . These may cause calcium deposit body tissue . Calcium deposit cause arthritis ( joint pain swell ) , muscle inflammation , itching , gangrene ( death soft tissue ) , heart lung problem . New evidence suggest secondary HPT associate cardiovascular disease increase death risk . The purpose study evaluate effect cinacalcet ( cinacalcet HCl Sensipar®/Mimpara® ) cardiovascular event ( heart blood vessel ) death chronic kidney disease ( CKD ) patient secondary hyperparathyroidism ( HPT ) receive dialysis . These event include death reason , heart attack episodes heart get enough oxygen , peripheral vascular disease ( narrow vessel carry blood leg , arm , stomach kidney ) , heart failure ( condition occur heart unable pump enough blood meet need 's body 's tissue )</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Inclusion : ≥ 18 year age Treated maintenance hemodialysis PTH ≥ 300 pg/mL ( 31.8 pmol/L ) serum calcium ≥ 8.4mg/dL ( 2.1 mmol/L ) Ca x P ≥ 45 mg2*/dL2 ( 3.63 mmol2/L2 ) Exclusion : Parathyroidectomy 12 week date inform consent Received therapy cinacalcet within 3 month randomization Hospitalization within 12 week randomization follow event : a. Myocardial ischemia b. Unstable angina c. Heart Failure ( HF ) ( include unplanned presentation health care facility would require mechanical intervention [ i.e. , unplanned dialysis treatment ] ) d. Peripheral vascular disease ( dialysis vascular access revision ) e. Stroke History seizure within 12 week prior randomization Scheduled date kidney transplant know live donor Anticipated parathyroidectomy within 6 month randomization instance , 2 refers square .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cinacalcet HCl</keyword>
	<keyword>Cinacalcet</keyword>
	<keyword>AMG 073</keyword>
	<keyword>Sensipar</keyword>
	<keyword>Mimpara</keyword>
	<keyword>Calcimimetic</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>CKD</keyword>
	<keyword>Secondary hyperparathyroidism ( HPT )</keyword>
</DOC>